AstraZeneca PLC (AZN)
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AZN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $270.40B
- P/E (TTM)
- 24.66
- Forward P/E
- 15.41
- EPS (TTM)
- $7.07
- Dividend yield
- 1.85% ($3.23)
- Ex-dividend date
- Feb 19, 2026
- 52-week range
- 153.41 – 212.71
- Day range
- 174.06 – 177.47
- Volume / Avg
- 2.02M / 2.93M
- Beta
- —
- Shares outstanding
- 1.55B
52-week range
AZN stock today
Shares of AstraZeneca (AZN) finished lower on Nov 20 at $174.35, a drop of 0.60% or $1.06 per share, versus the S&P 500's 3.70% decline. Shares are 18.0% below their 52-week high of $212.71, set on Feb 18, 2026 and 13.6% above the 52-week low of $153.41, in the middle of the past year's range. AZN is down 5.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.2%.
At 24.7x trailing earnings, AstraZeneca trades below the peer-group median of 30.9x. Its forward P/E of 15.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AstraZeneca pays an annual dividend of $3.23 per share, a 1.85% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About AstraZeneca
Company profileAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
- Headquarters
- Cambridge
- Employees
- 96,100
- IPO year
- 2026
- Website
- astrazeneca.com
Financial highlights
Full financialsIn fiscal 2025, AstraZeneca generated $58.74 billion in revenue, up 8.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $10.22 billion (+45.3% year over year), for a net margin of 17.4% versus a median of 12.0% in the prior 5 years. Gross margin was 81.9% (up from 81.1%) and operating margin 23.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Growth | +8.63% | +18.03% | +3.29% | +18.53% | +40.58% |
| Net income | $10.22B | $7.04B | $5.96B | $3.29B | $112.00M |
| EPS (diluted) | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$209.91+20.40%
- Strong buy 2
- Buy 7
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 30, 2026
- EPS actual vs est.
- $2.38 vs $2.60
- Surprise
- -8.46%
Dividends
Dividend history- Annual dividend
- $3.23
- Dividend yield
- 1.85%
- Last payment
- $2.15
- Ex-dividend date
- Feb 19, 2026
AZN news
All AZN news- AstraZeneca leads European big pharma on growth, pipeline depthInvesting.com
- FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer DrugNasdaqAZN, ADPT, SMMT, ACIU
- AstraZeneca's Sone-Ve Receives FDA Priority Review For Advanced Gastric And GEJ CancersNasdaq
- AstraZeneca wins FDA priority review for gastric cancer therapySeeking Alpha
- AstraZeneca's Sone-Ve Receives FDA Priority Review For Advanced Gastric CancerNasdaqAZN, HEI.A
- Tempus AI to receive $200M as AstraZeneca extends oncology dealSeeking AlphaTEM, AZN
- The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV FinancialNasdaqAZN, ETN, LIN, FRAF
- CSPC Pharma's Profit More Than Doubles On AstraZeneca Deal, Pipeline Advances Across Key ProgramsNasdaqHEI.A, AZN
AstraZeneca peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVSNovartis AG | 150.47 | -0.50% | $284.18B | vs AZN |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs AZN |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs AZN |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs AZN |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs AZN |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs AZN |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs AZN |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs AZN |
Indexes, lists and sector
AstraZeneca stock FAQ
What is AstraZeneca's stock price today?
AZN last traded at $174.35 as of Nov 20, 4:00 PM EST, down 0.60% on the day. Prices are delayed at least 15 minutes.
Does AstraZeneca pay a dividend?
Yes. AstraZeneca pays $3.23 per share annually, a 1.85% yield. The most recent dividend of $2.15 had an ex-dividend date of Feb 19, 2026.
What is AZN's P/E ratio?
AZN trades at a trailing P/E ratio of 24.66 and a forward P/E of 15.41, compared with a median of 30.9 for its closest peers.
Who is AstraZeneca's CEO?
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. is the chief executive officer of AstraZeneca PLC, which has about 96,100 employees.
Has AZN ever split its stock?
Yes. The most recent AZN stock split was a 1-for-2 split on Feb 2, 2026, one of 3 splits on record.
What is the AZN 52-week high?
The 52-week high for AZN is $212.71 and the 52-week low is $153.41. The stock is currently 18.0% below its high.